Description:

This lecture will outline and describe the current understanding of thyroid eye disease (TED) and its interrelation with Graves' Disease.  It will describe incidence, risk factors, and associated systemic signs, symptoms, and pathophysiology including Rundle's curve.  We will discuss treatment options for TED including the recent FDA approval of Teprotumumab, its clinical trials, study endpoints, and adverse reactions.  Masquerading ocular findings that may be early signs of TED will be described as well as lab testing that can help with the early detection of TED will be discussed.  Doctors have a knowledge need for this practice gap which means having the knowledge of how to detect, diagnose, and treat TED in an integrated, multidisciplinary method.

Course Code:

AOA255-SD

Speaker(s):

Jacob Lang, O.D.
drjakelang@gmail.com

Selina McGee, O.D.
drmcgee@bespokevision.org

Credits:

1

AOA Expiration Date:

4/20/2025

Related News

Ask the Coding Experts

You ask, the experts answer. The AOA Coding and Reimbursement Committee supports the AOA's strategic direction to develop and value procedural (CPT), diagnostic (ICD-10) and supply codes (HCPCS). Members can submit questions regarding medical records and coding to askthecodingexpert@aoa.org. Here are the latest questions.

AOA on Capitol Hill 2025: Live News Updates

Welcome to the official news hub for AOA on Capitol Hill 2025! Follow along with the AOA's exclusive coverage from optometry's single-largest federal advocacy event in Washington, D.C., and learn about the issues 600 of our colleagues championed on Capitol Hill.